Tipasertideg

Sanofi has initiated a first-in-human study of SAR447971 (also known as KT-485), an oral small-molecule IRAK4 targeted protein degrader discovered by Cambridge, Massachusetts-based Kymera Therapeutics (Nasdaq: KYMR), in patients with hidradenitis suppurativa — a chronic, painful inflammatory skin disease with limited oral treatment options. The trial is notable because SAR447971 is a second-generation compound, developed explicitly to improve on the potency and selectivity profile of its predecessor, KT-474 (SAR444656), which Sanofi had previously advanced into Phase II before discontinuing that program. Trial design and population The Phase I program (NCT07629336) comprises three sequential substudies enrolling approximately 114 participants in total at a single site in Leiden, Netherlands. The first two cohorts — a single ascending dose study (SAD20411, up to 46 healthy volunteers) and a multiple ascending dose study (MAD20412, up to 48 healthy volunteers) — are randomized, double-blind, and placebo-controlled, with the SAD arm also incorporating a food effect evaluation to characterize how fed versus fasted conditions affect oral absorption. A third open-label multiple ascending dose cohort (MAD24339) will enroll up to 20 patients with confirmed HS, defined by lesions in at least two distinct anatomic areas with at least one site at Hurley Stage II or III and a total abscess and nodule count of four or more. Primary completion is anticipated in Q1 2028. Primary endpoints across all three cohorts assess safety and tolerability through adverse event incidence, laboratory abnormalities, vital sign changes, and ECG parameters. The Sanofi clinical trial is registered under NCT07629336 according to the trial record. Mechanism and research context IRAK4 is a serine/threonine kinase that sits at a convergence point in innate immune signaling, mediating downstream inflammatory responses triggered by Toll-like receptors and interleukin-1 family cytokines. In HS, dysregulated innate immune activation drives the follicular inflammation, abscess formation, and sinus tract development that characterize the disease. SAR447971 is described by Kymera as a second-generation compound with increased potency and selectivity relative to KT-474, developed using Kymera’s proprietary Pegasus degrader discovery platform. The predecessor compound KT-474/SAR444656 had reached Phase II in both atopic dermatitis and HS before Sanofi discontinued that program and elected to advance the second-generation molecule instead. SAR447971’s improved selectivity profile is the stated rationale for the generational switch. Under the collaboration structure established in July 2020, Kymera discovered and characterized SAR447971 preclinically; Sanofi holds global inflammation and immunology development and commercialization rights. Kymera retains oncology rights and holds an option to co-develop and share US profits on a 50/50 basis. Kymera is eligible for up to USD 975 million in collaboration milestones, according to the company’s investor disclosures. Among active programs, Eli Lilly’s povorcitinib (LY3471851), a selective IRAK4 kinase inhibitor currently in Phase III for HS, represents the closest mechanistic comparator in the same indication, though it acts through inhibition rather than degradation and therefore preserves IRAK4 scaffolding function. SAR447971’s differentiation claim rests on whether complete protein elimination produces meaningfully greater or more durable pathway suppression. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Copyright © 2026. AllSci Corp. All rights reserved.

Gilead Sciences (Nasdaq: GILD) exercised its option to exclusively license KT-200, an oral CDK2 molecular glue degrader, from Kymera Therapeutics (Nasdaq: KYMR), triggering a USD 45 million milestone payment. Kymera has to date triggered total realized payments under the deal of USD 85 million. Gilead will now advance KT-200 into IND-enabling studies, targeting an IND filing in 2027. The original collaboration, signed in June 2025, was structured as an exclusive license option, with total potential value of up to USD 750 million and tiered royalties on net product sales. The USD 40 million paid at signing, combined with the USD 45 million option exercise fee now triggered, accounts for the USD 85 million in payments to date. Gilead holds global rights to develop, manufacture, and commercialize all products resulting from the collaboration. Deal context KT-200 is described by Kymera as a molecular glue degrader of CDK2, a serine/threonine kinase that regulates the G1/S transition in the cell cycle and is frequently dysregulated in solid tumors. Unlike conventional CDK2 inhibitors, which occupy the kinase active site without eliminating the protein, a molecular glue degrader works by inducing proximity between CDK2 and an E3 ubiquitin ligase, triggering ubiquitination and subsequent destruction of the target by the proteasome. The compound is orally administered and, according to Kymera’s preclinical data, achieved low-nanomolar CDK2 degradation with activity in CCNE1-amplified and overexpressed cell lines and in vivo tumor models, along with brain-penetrant potential. CDK2 has drawn particular attention in breast cancer, where CCNE1 amplification is associated with resistance to CDK4/6 inhibitors such as palbociclib and ribociclib. The rationale for degrading rather than inhibiting CDK2 centers on selectivity and depth of target suppression: traditional CDK2 inhibitors can interfere with closely related kinases, while a degrader approach, in principle, removes the protein entirely. Kymera’s press materials characterize KT-200 as potentially first-in-class within the molecular glue degrader modality for this target. Nevertheless, the molecule enters a crowded CDK2 landscape where selective inhibitors from Pfizer (PF-07104091) and Incyte (INCB123667) are already in clinical trials, while direct degrader competition stems from NiKang’s dual CDK2/4 candidate NKT5097 and Monte Rosa’s upcoming 2026 IND for MRT-51443. Kymera’s molecular glue strategy aims to differentiate by offering the deeper target suppression of a degrader with potentially superior selectivity over CDK1, a common stumbling block for traditional small-molecule inhibitors. Kymera, founded in 2016 and based in Watertown, Massachusetts, built its pipeline around targeted protein degradation. Its most advanced active clinical program is KT-621, an oral STAT6 degrader in Phase II, while its partnered IRAK4 program with Sanofi has advanced to KT-485/SAR447971 after Sanofi decided not to further develop first-generation KT-474. KT-200 is expected to be the first molecular glue discovered by Kymera to enter the clinic, expanding the company’s degrader toolkit beyond its earlier heterobifunctional PROTAC programs. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website